Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | POLA1 | P09884 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20840564 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL20840509 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL20840512 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL19816780 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL19813676 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL12227027 | 0.95 | CYP3A4 (0.63) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL24239554 | 0.94 | CYP3A4 (0.66) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL12248662 | 0.94 | CYP3A4 (0.66) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL23597930 | 0.94 | CYP3A4 (0.66) | CYP3A4CYP2C9POLA1PDE4DPDE3A | |
| SCHEMBL18341749 | 0.93 | CYP3A4 (0.55) | CYP3A4CYP2C9POLA1PDE4DPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684374-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | Riboscience LLC (US) | 2020-07-29 | — | — | EP | claimed |
| US-20190231804-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2019-08-01 | — | — | US | claimed |
| WO-2019060740-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2019-03-28 | — | — | WO | claimed |
| US-11351186-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | RIBOSCIENCE LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210046100-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2021-02-18 | — | — | US | disclosed |
| EP-3684374-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | Riboscience LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10682369-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | RIBOSCIENCE LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190231804-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2019-08-01 | — | — | US | disclosed |
| WO-2019060740-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231804-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | CYP3A4 864/4885CYP2C9 2255/4885POLA1 116/4885 |
| US-10682369-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | NSUN2, RNGTT, RNMT | CYP3A4 869/4885CYP2C9 2272/4885POLA1 119/4885 |
| US-11351186-B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | NSUN2, RNGTT, RNMT | CYP3A4 869/4885CYP2C9 2272/4885POLA1 119/4885 |
| US-20210046100-A1 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | CYP3A4 864/4885CYP2C9 2255/4885POLA1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.